{"id":341289,"date":"2025-08-20T14:28:50","date_gmt":"2025-08-20T14:28:50","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/news-events\/data\/how-to-buy-sarepta-therapeutics\/"},"modified":"2025-08-20T14:28:50","modified_gmt":"2025-08-20T14:28:50","slug":"how-to-buy-sarepta-therapeutics","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sarepta-therapeutics\/","title":{"rendered":"How to buy Sarepta Therapeutics, Inc. (SRPT) shares &#8211; Investment in Sarepta Therapeutics, Inc. (SRPT) stock"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334063,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-341289","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"How to Buy Sarepta Therapeutics, Inc. (SRPT) Shares - Investment in Sarepta Therapeutics, Inc. (SRPT) Stock","h1_source":{"label":"H1","type":"text","formatted_value":"How to Buy Sarepta Therapeutics, Inc. (SRPT) Shares - Investment in Sarepta Therapeutics, Inc. (SRPT) Stock"},"description":"Learn how to invest in Sarepta Therapeutics (SRPT) stock, current price $20.18, with expert analysis on risks, opportunities, and step-by-step buying process for 2025.","description_source":{"label":"Description","type":"textarea","formatted_value":"Learn how to invest in Sarepta Therapeutics (SRPT) stock, current price $20.18, with expert analysis on risks, opportunities, and step-by-step buying process for 2025."},"intro":"Thinking about investing in cutting-edge genetic medicine? Sarepta Therapeutics (SRPT) represents the thrilling frontier of biotech innovation\u2014but also its heart-pounding risks. This company stands at the crossroads of revolutionary science and regulatory challenges, making it one of 2025's most talked-about stocks. We'll break down everything from current price action to whether this biotech gamble could pay off big.","intro_source":{"label":"Intro","type":"text","formatted_value":"Thinking about investing in cutting-edge genetic medicine? Sarepta Therapeutics (SRPT) represents the thrilling frontier of biotech innovation\u2014but also its heart-pounding risks. This company stands at the crossroads of revolutionary science and regulatory challenges, making it one of 2025's most talked-about stocks. We'll break down everything from current price action to whether this biotech gamble could pay off big."},"body_html":"<h2>\ud83d\udcc8 SRPT Stock: Current Reality and Critical Dates<\/h2> <p>As of August 20, 2025, Sarepta Therapeutics (SRPT) trades at <strong>$20.18<\/strong>\u2014a price that tells a dramatic story of both promise and peril. Mark your calendar: <strong>November 2025<\/strong> is absolutely critical. That's when Sarepta releases its next earnings report, and given recent events, this could be a market-moving moment.<\/p> <h3>How Safety News Moves SRPT Stock<\/h3> <p>The past six months have been a rollercoaster where regulatory news became the main driver:<\/p> <ul> <li><strong>March 18, 2025<\/strong>: First patient death disclosure \u2192 Stock dropped <strong>27%<\/strong> in single day<\/li> <li><strong>June 24, 2025<\/strong>: FDA investigation announcement \u2192 Additional <strong>15% decline<\/strong><\/li> <li><strong>July 17, 2025<\/strong>: Third patient death revealed \u2192 <strong>40% crash<\/strong> the next day<\/li> <li><strong>July 28, 2025<\/strong>: FDA clears restart for ambulatory patients \u2192 <strong>23% recovery bounce<\/strong><\/li> <\/ul> <p>The pattern is clear: negative safety news causes immediate severe drops, while any positive regulatory developments trigger sharp recoveries. This volatility makes timing absolutely everything with SRPT.<\/p> [cta_green text=\"Start trading\"]<h2>\ud83d\udd0d 6-Month Price Journey: From Hope to Crisis<\/h2> <p>SRPT's journey from February to August 2025 reads like a medical thriller:<\/p> <ul> <li><strong>February 2025<\/strong>: Trading around $85 (pre-crisis confidence)<\/li> <li><strong>March 2025<\/strong>: Plunged to $45 after first safety disclosure<\/li> <li><strong>June 2025<\/strong>: Fell to $32 on expanded FDA investigation<\/li> <li><strong>July 2025<\/strong>: Crashed to $19 after third patient death<\/li> <li><strong>August 2025<\/strong>: Recovered to $20.18 on partial FDA clearance<\/li> <\/ul> <p>That's a <strong>76% decline<\/strong> from peak to trough\u2014enough to test any investor's nerves. The recent bounce from $19 suggests some bargain hunting, but the technical damage remains severe.<\/p> <h2>\ud83d\udd2e Price Forecast: 2025-2030 Outlook<\/h2> <ul> <li><strong>2025 (Year-End)<\/strong>: $25-35 \u2192 <strong>HOLD<\/strong> (wait for November earnings clarity)<\/li> <li><strong>2026<\/strong>: $40-60 (assuming regulatory resolution and sales recovery)<\/li> <li><strong>2028<\/strong>: $80-120 (if gene therapy platform proves safe long-term)<\/li> <li><strong>2030<\/strong>: $100-150+ (potential blockbuster status if safety concerns resolved)<\/li> <\/ul> <p>The analyst consensus of $45.65 suggests <strong>126% upside potential<\/strong>, but with targets ranging from $7 to $170, nobody really knows. This is pure biotech speculation at its finest.<\/p> <h2>\u26a0\ufe0f Key Risks vs. Positive Signals<\/h2> <h3>Risks That Keep Traders Awake<\/h3> <ul> <li><strong>Regulatory extinction<\/strong>: FDA could completely pull ELEVIDYS approval<\/li> <li><strong>Litigation tsunami<\/strong>: Multiple class actions could cost billions (<a href=\"https:\/\/www.rgrdlaw.com\/cases-sarepta-therapeutics-inc-class-action-lawsuit-srpt.html\">Robbins Geller<\/a>)<\/li> <li><strong>Bankruptcy risk<\/strong>: $414M negative cash flow can't continue forever<\/li> <li><strong>Reputation damage<\/strong>: Trust in gene therapy platform shattered<\/li> <\/ul> <h3>Green Lights for Brave Investors<\/h3> <ul> <li><strong>FDA partial clearance<\/strong>: Ambulatory patients back on treatment (<a href=\"https:\/\/www.statnews.com\/2025\/07\/28\/sarepta-duchenne-elevidys-hold-ambulatory\/\">STAT News<\/a>)<\/li> <li><strong>Market dominance<\/strong>: Still leader in Duchenne muscular dystrophy treatment<\/li> <li><strong>Undervalued potential<\/strong>: 32% below intrinsic value according to DCF analysis<\/li> <li><strong>Short squeeze potential<\/strong>: Heavy short interest could fuel rapid recovery<\/li> <\/ul> <h2>\ud83d\udee1\ufe0f What Should a Beginner Trader Do Today?<\/h2> <ol> <li><strong>Wait for November earnings<\/strong>: Too much uncertainty right now<\/li> <li><strong>Start small if buying<\/strong>: No more than 2-3% of portfolio allocation<\/li> <li><strong>Set tight stop-losses<\/strong>: This stock can gap down 40% overnight<\/li> <li><strong>Diversify away risk<\/strong>: Pair with stable healthcare stocks<\/li> <\/ol> <p>Humorous take: \"Trading SRPT is like performing heart surgery without anesthesia\u2014thrilling if you survive, but the patient might die on the table.\"<\/p> <h2>\u2705 How to Buy Sarepta Therapeutics, Inc. (SRPT) Shares - Step by Step<\/h2> <table> <thead> <tr><th>Step<\/th><th>Action<\/th><th>Why It Matters<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Choose trading platform<\/td><td>Must offer NASDAQ access for US biotech stocks<\/td><\/tr> <tr><td>2<\/td><td>Complete account funding<\/td><td>Start with small amount given high volatility<\/td><\/tr> <tr><td>3<\/td><td>Search \"SRPT\" ticker<\/td><td>Use exact symbol, not company name<\/td><\/tr> <tr><td>4<\/td><td>Select order type<\/td><td>Limit orders only\u2014never market orders with this volatility<\/td><\/tr> <tr><td>5<\/td><td>Review and confirm<\/td><td>Check commission rates under 0.5%<\/td><\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Why Pocket Option Fits Volatile Biotech Trading<\/h2> <p>Trading stocks like SRPT requires flexibility that Pocket Option delivers perfectly:<\/p> <ul> <li><strong>$5 minimum deposit<\/strong> \u2014 test strategies with real money without risking your rent<\/li> <li><strong>Instant verification<\/strong> \u2014 upload any ID and start trading in minutes, not days<\/li> <li><strong>Crypto-friendly withdrawals<\/strong> \u2014 get your profits out quickly when opportunities arise<\/li> <\/ul> <p>For biotech stocks that can move 40% in a day, you need platform agility that traditional brokers simply can't match.<\/p> <h2>\ud83c\udf0d Sarepta in 2025: Crisis and Opportunity<\/h2> <p>Sarepta Therapeutics dominates the Duchenne muscular dystrophy treatment market with three FDA-approved therapies, but 2025 will be remembered as their near-death experience. The company maintains leadership in precision genetic medicine despite recent setbacks, with a market cap of $1.97B and $2.48B in annual revenue (<a href=\"https:\/\/stockanalysis.com\/stocks\/srpt\/\">StockAnalysis<\/a>).<\/p> <p><strong>Interesting Fact<\/strong>: In July 2025, Sarepta announced layoffs of 500 employees (36% of workforce) to save $400M by 2026\u2014one of the largest biotech restructurings following safety issues (<a href=\"https:\/\/en.wikipedia.org\/wiki\/Sarepta_Therapeutics\">Wikipedia<\/a>).<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 SRPT Stock: Current Reality and Critical Dates<\/h2>\n<p>As of August 20, 2025, Sarepta Therapeutics (SRPT) trades at <strong>$20.18<\/strong>\u2014a price that tells a dramatic story of both promise and peril. Mark your calendar: <strong>November 2025<\/strong> is absolutely critical. That&#8217;s when Sarepta releases its next earnings report, and given recent events, this could be a market-moving moment.<\/p>\n<h3>How Safety News Moves SRPT Stock<\/h3>\n<p>The past six months have been a rollercoaster where regulatory news became the main driver:<\/p>\n<ul>\n<li><strong>March 18, 2025<\/strong>: First patient death disclosure \u2192 Stock dropped <strong>27%<\/strong> in single day<\/li>\n<li><strong>June 24, 2025<\/strong>: FDA investigation announcement \u2192 Additional <strong>15% decline<\/strong><\/li>\n<li><strong>July 17, 2025<\/strong>: Third patient death revealed \u2192 <strong>40% crash<\/strong> the next day<\/li>\n<li><strong>July 28, 2025<\/strong>: FDA clears restart for ambulatory patients \u2192 <strong>23% recovery bounce<\/strong><\/li>\n<\/ul>\n<p>The pattern is clear: negative safety news causes immediate severe drops, while any positive regulatory developments trigger sharp recoveries. This volatility makes timing absolutely everything with SRPT.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/en\/register\/\" class=\"po-cta-green\">Start trading\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udd0d 6-Month Price Journey: From Hope to Crisis<\/h2>\n<p>SRPT&#8217;s journey from February to August 2025 reads like a medical thriller:<\/p>\n<ul>\n<li><strong>February 2025<\/strong>: Trading around $85 (pre-crisis confidence)<\/li>\n<li><strong>March 2025<\/strong>: Plunged to $45 after first safety disclosure<\/li>\n<li><strong>June 2025<\/strong>: Fell to $32 on expanded FDA investigation<\/li>\n<li><strong>July 2025<\/strong>: Crashed to $19 after third patient death<\/li>\n<li><strong>August 2025<\/strong>: Recovered to $20.18 on partial FDA clearance<\/li>\n<\/ul>\n<p>That&#8217;s a <strong>76% decline<\/strong> from peak to trough\u2014enough to test any investor&#8217;s nerves. The recent bounce from $19 suggests some bargain hunting, but the technical damage remains severe.<\/p>\n<h2>\ud83d\udd2e Price Forecast: 2025-2030 Outlook<\/h2>\n<ul>\n<li><strong>2025 (Year-End)<\/strong>: $25-35 \u2192 <strong>HOLD<\/strong> (wait for November earnings clarity)<\/li>\n<li><strong>2026<\/strong>: $40-60 (assuming regulatory resolution and sales recovery)<\/li>\n<li><strong>2028<\/strong>: $80-120 (if gene therapy platform proves safe long-term)<\/li>\n<li><strong>2030<\/strong>: $100-150+ (potential blockbuster status if safety concerns resolved)<\/li>\n<\/ul>\n<p>The analyst consensus of $45.65 suggests <strong>126% upside potential<\/strong>, but with targets ranging from $7 to $170, nobody really knows. This is pure biotech speculation at its finest.<\/p>\n<h2>\u26a0\ufe0f Key Risks vs. Positive Signals<\/h2>\n<h3>Risks That Keep Traders Awake<\/h3>\n<ul>\n<li><strong>Regulatory extinction<\/strong>: FDA could completely pull ELEVIDYS approval<\/li>\n<li><strong>Litigation tsunami<\/strong>: Multiple class actions could cost billions (<a href=\"https:\/\/www.rgrdlaw.com\/cases-sarepta-therapeutics-inc-class-action-lawsuit-srpt.html\">Robbins Geller<\/a>)<\/li>\n<li><strong>Bankruptcy risk<\/strong>: $414M negative cash flow can&#8217;t continue forever<\/li>\n<li><strong>Reputation damage<\/strong>: Trust in gene therapy platform shattered<\/li>\n<\/ul>\n<h3>Green Lights for Brave Investors<\/h3>\n<ul>\n<li><strong>FDA partial clearance<\/strong>: Ambulatory patients back on treatment (<a href=\"https:\/\/www.statnews.com\/2025\/07\/28\/sarepta-duchenne-elevidys-hold-ambulatory\/\">STAT News<\/a>)<\/li>\n<li><strong>Market dominance<\/strong>: Still leader in Duchenne muscular dystrophy treatment<\/li>\n<li><strong>Undervalued potential<\/strong>: 32% below intrinsic value according to DCF analysis<\/li>\n<li><strong>Short squeeze potential<\/strong>: Heavy short interest could fuel rapid recovery<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f What Should a Beginner Trader Do Today?<\/h2>\n<ol>\n<li><strong>Wait for November earnings<\/strong>: Too much uncertainty right now<\/li>\n<li><strong>Start small if buying<\/strong>: No more than 2-3% of portfolio allocation<\/li>\n<li><strong>Set tight stop-losses<\/strong>: This stock can gap down 40% overnight<\/li>\n<li><strong>Diversify away risk<\/strong>: Pair with stable healthcare stocks<\/li>\n<\/ol>\n<p>Humorous take: &#8220;Trading SRPT is like performing heart surgery without anesthesia\u2014thrilling if you survive, but the patient might die on the table.&#8221;<\/p>\n<h2>\u2705 How to Buy Sarepta Therapeutics, Inc. (SRPT) Shares &#8211; Step by Step<\/h2>\n<table>\n<thead>\n<tr>\n<th>Step<\/th>\n<th>Action<\/th>\n<th>Why It Matters<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Choose trading platform<\/td>\n<td>Must offer NASDAQ access for US biotech stocks<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Complete account funding<\/td>\n<td>Start with small amount given high volatility<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>Search &#8220;SRPT&#8221; ticker<\/td>\n<td>Use exact symbol, not company name<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Select order type<\/td>\n<td>Limit orders only\u2014never market orders with this volatility<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Review and confirm<\/td>\n<td>Check commission rates under 0.5%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Why Pocket Option Fits Volatile Biotech Trading<\/h2>\n<p>Trading stocks like SRPT requires flexibility that Pocket Option delivers perfectly:<\/p>\n<ul>\n<li><strong>$5 minimum deposit<\/strong> \u2014 test strategies with real money without risking your rent<\/li>\n<li><strong>Instant verification<\/strong> \u2014 upload any ID and start trading in minutes, not days<\/li>\n<li><strong>Crypto-friendly withdrawals<\/strong> \u2014 get your profits out quickly when opportunities arise<\/li>\n<\/ul>\n<p>For biotech stocks that can move 40% in a day, you need platform agility that traditional brokers simply can&#8217;t match.<\/p>\n<h2>\ud83c\udf0d Sarepta in 2025: Crisis and Opportunity<\/h2>\n<p>Sarepta Therapeutics dominates the Duchenne muscular dystrophy treatment market with three FDA-approved therapies, but 2025 will be remembered as their near-death experience. The company maintains leadership in precision genetic medicine despite recent setbacks, with a market cap of $1.97B and $2.48B in annual revenue (<a href=\"https:\/\/stockanalysis.com\/stocks\/srpt\/\">StockAnalysis<\/a>).<\/p>\n<p><strong>Interesting Fact<\/strong>: In July 2025, Sarepta announced layoffs of 500 employees (36% of workforce) to save $400M by 2026\u2014one of the largest biotech restructurings following safety issues (<a href=\"https:\/\/en.wikipedia.org\/wiki\/Sarepta_Therapeutics\">Wikipedia<\/a>).<\/p>\n"},"faq":[{"question":"Is now a good time to buy SRPT stock?","answer":"Wait until November earnings for clearer regulatory picture. The risk\/reward isn't favorable enough yet."},{"question":"What's the biggest risk with Sarepta investment?","answer":"Complete FDA rejection of their gene therapy platform, which could make the stock worthless."},{"question":"How long should I hold SRPT if I buy?","answer":"Minimum 2-3 year horizon. This isn't a quick trade\u2014it's a binary bet on regulatory survival."},{"question":"What percentage of my portfolio should be SRPT?","answer":"No more than 3-5% maximum. This is speculative biotech, not stable blue-chip."},{"question":"Are there dividend payments?","answer":"No dividends. Sarepta reinvests all cash into R&D and managing current crises."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Is now a good time to buy SRPT stock?","answer":"Wait until November earnings for clearer regulatory picture. The risk\/reward isn't favorable enough yet."},{"question":"What's the biggest risk with Sarepta investment?","answer":"Complete FDA rejection of their gene therapy platform, which could make the stock worthless."},{"question":"How long should I hold SRPT if I buy?","answer":"Minimum 2-3 year horizon. This isn't a quick trade\u2014it's a binary bet on regulatory survival."},{"question":"What percentage of my portfolio should be SRPT?","answer":"No more than 3-5% maximum. This is speculative biotech, not stable blue-chip."},{"question":"Are there dividend payments?","answer":"No dividends. Sarepta reinvests all cash into R&D and managing current crises."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>How to buy Sarepta Therapeutics, Inc. (SRPT) shares - Investment in Sarepta Therapeutics, Inc. (SRPT) stock<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sarepta-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"How to buy Sarepta Therapeutics, Inc. (SRPT) shares - Investment in Sarepta Therapeutics, Inc. (SRPT) stock\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sarepta-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-20T14:28:50+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sarepta-therapeutics\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sarepta-therapeutics\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"How to buy Sarepta Therapeutics, Inc. (SRPT) shares &#8211; Investment in Sarepta Therapeutics, Inc. (SRPT) stock\",\"datePublished\":\"2025-08-20T14:28:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sarepta-therapeutics\/\"},\"wordCount\":17,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sarepta-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals9-scaled.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sarepta-therapeutics\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sarepta-therapeutics\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sarepta-therapeutics\/\",\"name\":\"How to buy Sarepta Therapeutics, Inc. (SRPT) shares - Investment in Sarepta Therapeutics, Inc. (SRPT) stock\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sarepta-therapeutics\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sarepta-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals9-scaled.webp\",\"datePublished\":\"2025-08-20T14:28:50+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sarepta-therapeutics\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sarepta-therapeutics\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sarepta-therapeutics\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals9-scaled.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals9-scaled.webp\",\"width\":2560,\"height\":1429},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sarepta-therapeutics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"How to buy Sarepta Therapeutics, Inc. (SRPT) shares &#8211; Investment in Sarepta Therapeutics, Inc. (SRPT) stock\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/en\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/en\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"How to buy Sarepta Therapeutics, Inc. (SRPT) shares - Investment in Sarepta Therapeutics, Inc. (SRPT) stock","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sarepta-therapeutics\/","og_locale":"en_US","og_type":"article","og_title":"How to buy Sarepta Therapeutics, Inc. (SRPT) shares - Investment in Sarepta Therapeutics, Inc. (SRPT) stock","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sarepta-therapeutics\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-20T14:28:50+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sarepta-therapeutics\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sarepta-therapeutics\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"How to buy Sarepta Therapeutics, Inc. (SRPT) shares &#8211; Investment in Sarepta Therapeutics, Inc. (SRPT) stock","datePublished":"2025-08-20T14:28:50+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sarepta-therapeutics\/"},"wordCount":17,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sarepta-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals9-scaled.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sarepta-therapeutics\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sarepta-therapeutics\/","url":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sarepta-therapeutics\/","name":"How to buy Sarepta Therapeutics, Inc. (SRPT) shares - Investment in Sarepta Therapeutics, Inc. (SRPT) stock","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sarepta-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sarepta-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals9-scaled.webp","datePublished":"2025-08-20T14:28:50+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sarepta-therapeutics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sarepta-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sarepta-therapeutics\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals9-scaled.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals9-scaled.webp","width":2560,"height":1429},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sarepta-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/en\/"},{"@type":"ListItem","position":2,"name":"How to buy Sarepta Therapeutics, Inc. (SRPT) shares &#8211; Investment in Sarepta Therapeutics, Inc. (SRPT) stock"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/en\/#website","url":"https:\/\/pocketoption.com\/blog\/en\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/en\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":341320,"slug":"how-to-buy-sarepta-therapeutics","post_title":"Comment acheter des actions de Sarepta Therapeutics, Inc. (SRPT) - Investir dans les actions de Sarepta Therapeutics, Inc. (SRPT)","href":"https:\/\/pocketoption.com\/blog\/fr\/news-events\/signal\/how-to-buy-sarepta-therapeutics\/"},"it_IT":{"locale":"it_IT","id":341321,"slug":"how-to-buy-sarepta-therapeutics","post_title":"Come acquistare azioni Sarepta Therapeutics, Inc. (SRPT) - Investire in azioni Sarepta Therapeutics, Inc. (SRPT)","href":"https:\/\/pocketoption.com\/blog\/it\/news-events\/signal\/how-to-buy-sarepta-therapeutics\/"},"pl_PL":{"locale":"pl_PL","id":341322,"slug":"how-to-buy-sarepta-therapeutics","post_title":"Jak kupi\u0107 akcje Sarepta Therapeutics, Inc. (SRPT) - Inwestycja w akcje Sarepta Therapeutics, Inc. (SRPT)","href":"https:\/\/pocketoption.com\/blog\/pl\/news-events\/signal\/how-to-buy-sarepta-therapeutics\/"},"es_ES":{"locale":"es_ES","id":341328,"slug":"how-to-buy-sarepta-therapeutics","post_title":"C\u00f3mo comprar acciones de Sarepta Therapeutics, Inc. (SRPT) - Inversi\u00f3n en acciones de Sarepta Therapeutics, Inc. (SRPT)","href":"https:\/\/pocketoption.com\/blog\/es\/news-events\/signal\/how-to-buy-sarepta-therapeutics\/"},"th_TH":{"locale":"th_TH","id":341325,"slug":"how-to-buy-sarepta-therapeutics","post_title":"\u0e27\u0e34\u0e18\u0e35\u0e0b\u0e37\u0e49\u0e2d\u0e2b\u0e38\u0e49\u0e19 Sarepta Therapeutics, Inc. (SRPT) - \u0e01\u0e32\u0e23\u0e25\u0e07\u0e17\u0e38\u0e19\u0e43\u0e19\u0e2b\u0e38\u0e49\u0e19 Sarepta Therapeutics, Inc. (SRPT)","href":"https:\/\/pocketoption.com\/blog\/th\/news-events\/signal\/how-to-buy-sarepta-therapeutics\/"},"tr_TR":{"locale":"tr_TR","id":341324,"slug":"how-to-buy-sarepta-therapeutics","post_title":"Sarepta Therapeutics, Inc. (SRPT) Hisseleri Nas\u0131l Al\u0131n\u0131r - Sarepta Therapeutics, Inc. (SRPT) Hisse Yat\u0131r\u0131m\u0131","href":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-sarepta-therapeutics\/"},"vt_VT":{"locale":"vt_VT","id":341329,"slug":"how-to-buy-sarepta-therapeutics","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Sarepta Therapeutics, Inc. (SRPT) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Sarepta Therapeutics, Inc. (SRPT)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-sarepta-therapeutics\/"},"pt_AA":{"locale":"pt_AA","id":341323,"slug":"how-to-buy-sarepta-therapeutics","post_title":"Como comprar a\u00e7\u00f5es da Sarepta Therapeutics, Inc. (SRPT) - Investimento em a\u00e7\u00f5es da Sarepta Therapeutics, Inc. (SRPT)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-sarepta-therapeutics\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts\/341289","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/comments?post=341289"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts\/341289\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/media\/334063"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/media?parent=341289"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/categories?post=341289"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/tags?post=341289"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}